Longevity, tumor, and physical vitality in rats consuming ginsenoside Rg1.

Background: Effects of the major ginsenoside Rg1 on mammalian longevity and physical vitality are rarely reported.

Purpose: To examine longevity, tumor, and spontaneous locomotor activity in rats consuming Rg1.

Methods: A total of 138 Wistar rats were randomized into 2 groups: control (N = 69) and Rg1 (N = 69). Rg1 (0.1 mg/kg per day) were orally supplemented from 6 months of age until natural death. Spontaneous mobility was measured by video-tracking together with body composition (dual energy x-ray absorptiometry) and inflammation markers at 5, 14, 21, and 28 months of age.

Results: No significant differences in longevity (control: 706 days; Rg1: 651 days,  = 0.77) and tumor incidence (control: 19%; Rg1: 12%,  = 0.24) were observed between the two groups. Movement distance in the control group declined significantly by ∼60% at 21 months of age, together with decreased TNF-α ( = 0.01) and increased IL-10 ( = 0.02). However, the movement distance in the Rg1 group was maintained ∼50% above the control groups ( = 0.01) at 21 months of age with greater magnitudes of TNF-α decreases and IL-10 increases. Glucose, insulin, and body composition (bone, muscle and fat percentages) were similar for both groups during the entire observation period.

Conclusion: The results of the study suggest a delay age-dependent decline in physical vitality during late life by lifelong Rg1 consumption. This improvement is associated with inflammatory modulation. Significant effects of Rg1 on longevity and tumorigenesis were not observed.